Click on image to view larger version.

Figure 1 (A to C) Single photon emission computed tomography myocardial perfusion imaging orthogonal plane images before pravastatin therapy (baseline), at six weeks, and at six months of pravastatin therapy in a typical patient with reduced summed stress score by six months. Consistent with randomized controlled trials, pravastatin 40 mg was administered on a non-dose titrated basis. Stress perfusion defect size declined in 11 (48%) and was stable in 10 (43%) of 23 patients completing the trial. (D) Automated quantitative analyses of defect (percent of left ventricular hypoperfusion) size (left images) and global extent (right images) at baseline, six weeks, and six months of pravastatin therapy. Quantitative analyses verified improved average stress perfusion by six months in the study population.